HR Works: The Podcast for Human Resources

The episode contains a handful of genuinely informative points - impairment windows by consumption type, the biology of fat solubility, and calibrated detection windows per test method - but these are interspersed with substantial filler, host affirmations, and vendor positioning. The density of actionable insight per minute is moderate at best.

“over 10% of oral fluid drug tests performed across the country were positive for cannabis. And the next most common drug was amphetamine at 1.2%”

“when someone smokes cannabis a moderate user... smokes a single cannabis cigarette they are typically impaired for between four and five hours... And then when we see cannabis consumed as an edible, that acute impairment window... lasts closer to around 11 hours”

The episode is primarily explanatory rather than original - it conveys established regulatory and biological facts rather than offering contrarian or first-principles arguments. The fat-solubility explanation for why alcohol impairment thresholds don't translate to cannabis is the most intellectually fresh moment, but it's still textbook science, not novel insight.

“Cannabis is fat soluble. And one of the fattiest parts of your body is your brain. So as Delta 9 THC is circulating in your body, it is being pulled out of solution from your blood... and it's dissolving into the fatty tissues of your body”

“we might see the blood plasma levels drop, but the brain levels are still increasing. And so we can't necessarily correlate perfectly the blood level to an impairment level”

Kate Riley is a vendor GM with five years in the drug-testing space, giving her genuine domain knowledge; however, she is essentially a commercial operator for a product being promoted, not a senior HR practitioner, independent researcher, or policy authority who has managed drug programs at scale inside an employer organization.

“I have spent the last five years or so in this space with companies developing drug testing solutions”

“I'm, as you mentioned, the general manager for recent THC at Minder, working on our portfolio of THC testing solutions for the marketplace”

The guest cites the Quest Diagnostic Drug Testing Index by name, provides specific percentage figures for drug positivity rates, names exact nanogram-per-milliliter cutoffs, and gives concrete detection windows in hours - these are meaningfully specific. However, no named employer case studies, dollar figures, or legislative bill citations appear, keeping the score from going higher.

“over 10% of oral fluid drug tests performed across the country were positive for cannabis. And the next most common drug was amphetamine at 1.2%”

“oral fluid testing... if there's a cutoff of roughly 10 nanograms per milliliter... that gives you about an 11 or 12 hour detection window”

The host asks broad, open-ended setup questions and responds almost exclusively with affirmations ('Absolutely,' 'That's such a fascinating look'), never pushes back on vendor claims, and fails to probe ambiguities such as legal liability, cost of new testing methods, or false-positive rates. The interview functions as a polished promotional conversation rather than a rigorous dialogue.

“Absolutely. And I think that such a good point about you know the culture changing”

“That is so fascinating a look into the actual science behind all of this testing and use that a lot of people go unaware of”